Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JULY 30, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF IMMIX BIOPHARMA, INC. ("IMMIX" OR THE "COMPANY") (NASDAQ: IMMX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF IMMIX BIOPHARMA, INC. - IMMX

LOS ANGELES, JULY 21, 2026 (GLOBE NEWSWIRE) -- THE PORTNOY LAW FIRM ADVISES IMMIX BIOPHARMA , ( IMMIX " OR THE "COMPANY") ( NASDAQ : IMMX ) INVESTORS THAT THE FIRM HAS INITIATED AN INVESTIGATION INTO POSSIBLE SECURITIES FRAUD, AND MAY FILE A CLASS ACTION ON BEHALF OF INVESTORS.

IMMIX BIOPHARMA INVESTIGATED BY THE PORTNOY LAW FIRM

PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - JULY 20, 2026) - KEHOE LAW FIRM, P.C. IS INVESTIGATING POTENTIAL SECURITIES FRAUD CLAIMS ON BEHALF OF INVESTORS OF IMMIX BIOPHARMA, INC. ("IMMIX BIOPHARMA") (NASDAQ: IMMX).

IMMIX BIOPHARMA STOCK DROPS SIGNIFICANTLY ON NEWS OF CHIEF MEDICAL OFFICER ARREST - IMMX INVESTORS ENCOURAGED TO CONTACT KEHOE LAW FIRM, P.C. REGARDING POTENTIAL SECURITIES FRAUD CLAIMS

BOSTON, JULY 20, 2026 (GLOBE NEWSWIRE) -- BLOCK & LEVITON IS INVESTIGATING IMMIX BIOPHARMA (NASDAQ: IMMX) FOR POTENTIAL SECURITIES LAW VIOLATIONS. INVESTORS WHO HAVE LOST MONEY IN THEIR IMMIX BIOPHARMA INVESTMENT SHOULD CONTACT THE FIRM TO LEARN MORE ABOUT HOW THEY MIGHT RECOVER THOSE LOSSES.

IMMX ALERT: IMMIX BIOPHARMA INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS BY BLOCK & LEVITON; INVESTORS SHOULD CONTACT THE FIRM

 FINANCING INCLUDES LEADING U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS AND MUTUAL FUNDS  LOS ANGELES, CA, MAY 22, 2026 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A GLOBAL LEADER IN AL AMYLOIDOSIS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN REGISTERED OFFERING OF 16,778,524 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $8.94 PER SHARE. THE NET PROCEEDS TO IMMIX FROM THE OFFERING, AFTER DEDUCTING THE UNDERWRITING DISCOUNTS, COMMISSIONS AND OTHER OFFERING EXPENSES, WERE APPROXIMATELY $140.65 MILLION.

IMMIX BIOPHARMA ANNOUNCES CLOSING OF $150 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

LOS ANGELES, MAY 21, 2026 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A GLOBAL LEADER IN AL AMYLOIDOSIS, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN REGISTERED OFFERING OF 16,778,524 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $8.94 PER SHARE. THE GROSS PROCEEDS TO IMMIX FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS, COMMISSIONS AND OTHER OFFERING EXPENSES, ARE EXPECTED TO BE $150 MILLION. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT MAY 22, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

IMMIX BIOPHARMA ANNOUNCES PRICING OF $150 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

 OF FIRST 20 PATIENTS, ALL FOUR MRD-NEGATIVE PATIENTS HAVE CONVERTED TO COMPLETE RESPONSE (CR)   CR RATE NOW 95% (19 OF 20 PATIENTS)   ALL CRS REACHED WITHIN 1 YEAR OF FOLLOW-UP POST-DOSING   NO RELAPSES TO-DATE OBSERVED FOR PATIENTS WHO HAVE REACHED CR   ALL SUBSEQUENTLY ENROLLED PATIENTS FOR WHOM MRD RESULTS ARE AVAILABLE ARE MRD-NEGATIVE AT ONE MONTH   NEXT NEXICART-2 UPDATE EXPECTED LATE SEPTEMBER, 2026  LOS ANGELES, MAY 21, 2026 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A GLOBAL LEADER IN AL AMYLOIDOSIS, TODAY ANNOUNCED THAT ALL FOUR RELAPSED/REFRACTORY AL AMYLOIDOSIS MRD-NEGATIVE PATIENTS PRESENTED AT ASH 2025 HAVE CONVERTED TO COMPLETE RESPONSE (CR). THE NEXICART-2 CR RATE IS NOW 95% (19 OUT OF 20 PATIENTS).

IMMIX BIOPHARMA ANNOUNCES 95% COMPLETE RESPONSE RATE IN INTERIM UPDATE FROM RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL NEXICART-2

LOS ANGELES, CA, APRIL 09, 2026 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), THE GLOBAL LEADER IN RELAPSED/REFRACTORY AL AMYLOIDOSIS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE AND HOST INSTITUTIONAL INVESTOR MEETINGS AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE BEING HELD JUNE 2-4, 2026 IN NEW YORK, NY.

IMMIX BIOPHARMA TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

 FULL ENROLLMENT OF BLA-ENABLING TRIAL COMPLETE, PER PRIOR GUIDANCE   TOPLINE NEXICART-2 RESULTS EXPECTED Q3 2026, FOLLOWED BY BLA SUBMISSION AND PLANNED COMMERCIAL LAUNCH   ONBOARDED CHIEF MEDICAL OFFICER, FORMERLY OF MERCK AND JOHNSON & JOHNSON FOR BLA SUBMISSION 

IMMIX BIOPHARMA ANNOUNCES ENROLLMENT COMPLETION OF BLA-ENABLING RELAPSED/REFRACTORY AL AMYLOIDOSIS TRIAL NEXICART-2, AND UPCOMING MILESTONES

LOS ANGELES, CA, MARCH 03, 2026 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), THE GLOBAL LEADER IN RELAPSED/REFRACTORY AL AMYLOIDOSIS, TODAY ANNOUNCED THAT IT WILL PRESENT AND HOST INVESTOR MEETINGS AT THE FOLLOWING UPCOMING INSTITUTIONAL INVESTOR CONFERENCES:

Immix Biopharma, Inc.

IMMX

Price

Financial Reports

No items found.

Press Releases

Immix Biopharma, Inc.

IMMX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMMX